Salt inducible kinase inhibitors

A compound of Formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• V, X, and Z are each C, and W and Y are each N;
• or
• V, Y, and Z are each C, and W and X are each N;
• or
• V and Y are each C, and W, X, and Z are each N;
• U is CR3 or N;
• U′ is CR5 or N;
• U″ is CR6 or N;
• R1 is selected from 5 membered heteroaryl, ORa1, C(O)NRc1Rd1, and NRc1C(O)Rb1, wherein the 5 membered heteroaryl is optionally substituted with 1 or 2 independently selected R1A substituents;
• Ra1, Rb1, Rc1, and Rd1 are each independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl, and (5-10 membered heteroaryl)-C1-6 alkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl, and (5-10 membered heteroaryl)-C1-6 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R1A substituents;
• or Rc1 and Rd1, together with the nitrogen to which they are attached, come together to form a 10-14 membered heterocycloalkyl or 10-14 membered heteroaryl group, wherein the 10-14 membered heterocycloalkyl and 10-14 membered heteroaryl group are each optionally substituted with 1, 2, 3, or 4 independently selected R1A substituents;
• each R1A is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, C6-10 aryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, NO2, CN, wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with C1-4 alkoxy;
• R2 is selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 alkoxy;
• R3 is selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 alkoxy;
• R4 is selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl, (5-10 membered heteroaryl)-C1-6 alkyl, NO2, CN, ORa4, C(O)Rb4, C(O)NRc4Rd4, C(O)N(Rc4)NRc4Rd4, NRc4C(O)Rb4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, and NRc4C(O)ORa4, wherein the C6-10 aryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl, and (5-10 membered heteroaryl)-C1-6 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R4A substituents;
• Ra4, Rb4, Rc4, and Rd4 are each independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 alkoxy;
• each R4A is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 alkoxy;
• R5 is selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 alkoxy;
• or R4 and R5, together with the carbon atoms to which they are attached, come together to form a 5-6 membered aryl ring which is optionally substituted with 1, 2, 3, or 4 independently selected R7 substituents;
• R6 is selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, and C1-6 alkoxy;
• each R7 is independently selected from C6-10 aryl, C3-10 cycloalkyl, 4-14 membered heterocycloalkyl, 5-10 membered heteroaryl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl, (5-10 membered heteroaryl)-C1-6 alkyl, NO2, CN, and ORa7, wherein the C6-10 aryl, C3-10 cycloalkyl, 4-14 membered heterocycloalkyl, 5-10 membered heteroaryl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl, (5-10 membered heteroaryl)-C1-6 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R7A substituents;
• each Ra7 is independently selected from C6-10 aryl, C3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C6-10 aryl-C1-6 alkyl-, C3-10 cycloalkyl-C1-6 alkyl-, (4-10 membered heterocycloalkyl)-C1-6 alkyl, and (5-10 membered heteroaryl)-C1-6 alkyl;
• and each R7A is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 alkoxy, amino, C1-6 alkylamino, di(C1-6 alkyl) amino, phenyl, C3-6 cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, and wherein the C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with amino or C1-4 alkoxy.